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Real-time decision-makingInfectious disease epidemics present a difficult task for policymakers, requiring the implementation of
control strategies under significant time constraints and uncertainty. Mathematical models can be used
to predict the outcome of control interventions, providing useful information to policymakers in the
event of such an epidemic. However, these models suffer in the early stages of an outbreak from a lack
of accurate, relevant information regarding the dynamics and spread of the disease and the efficacy of
control. As such, recommendations provided by these models are often incorporated in an ad hoc fashion,
as and when more reliable information becomes available. In this work, we show that such trial-and-
error-type approaches to management, which do not formally take into account the resolution of uncer-
tainty and how control actions affect this, can lead to sub-optimal management outcomes. We compare
three approaches to managing a theoretical epidemic: a non-adaptive management (AM) approach that
does not use real-time outbreak information to adapt control, a passive AM approach that incorporates
real-time information if and when it becomes available, and an active AM approach that explicitly incor-
porates the future resolution of uncertainty through gathering real-time information into its initial rec-
ommendations. The structured framework of active AM encourages the specification of quantifiable
objectives, models of system behaviour and possible control and monitoring actions, followed by an iter-
ative learning and control phase that is able to employ complex control optimisations and resolve system
uncertainty. The result is a management framework that is able to provide dynamic, long-term projec-
tions to help policymakers meet the objectives of management. We investigate in detail the effect of dif-
ferent methods of incorporating up-to-date outbreak information. We find that, even in a highly
simplified system, the method of incorporating new data can lead to different results that may influence
initial policy decisions, with an active AM approach to management providing better information that
can lead to more desirable outcomes from an epidemic.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The management of infectious disease epidemics is a task beset
by difficulties. It requires satisfying the complex, and often con-
flicting, objectives of stakeholders, without complete knowledgeof how the disease will spread or the effect of control. Mathemat-
ical models have become a useful tool to aid in the decision-
making process, allowing the comparison of different strategies
through simulation (Keeling et al., 2001; Ferguson et al., 2001;
Keeling et al., 2003; Tildesley et al., 2006; Shea et al., 2014;
Bradbury et al., 2017; Probert et al., 2018; Li et al., 2017). However,
incomplete knowledge of the system can be a significant barrier to
providing relevant policy recommendations (Tildesley et al., 2006;
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2017; O’Neill et al., 1999; Lekone et al., 2006; Cauchemez and
Ferguson, 2008; Jewell et al., 2009,; Jewell et al., 2009; Elderd
et al., 2006). In the context of a novel outbreak, control strategies
must be decided upon and implemented quickly, leaving little time
to gather accurate information about the current outbreak, such as
the length of time an individual remains infectious or the efficacy
of a vaccine. As a result, the retrospective analyses of historic out-
breaks are often used to estimate such parameters. In such
instances, real-time information then may be ignored or used in
an ad hoc fashion as the outbreak progresses.
The adaptive management (AM) framework, more specifically
‘active’ AM, has been proposed as a way to tackle some of the prob-
lems posed by system uncertainty in epidemic management (Merl
et al., 2009; Shea et al., 2014; Bradbury et al., 2017; Li et al., 2017).
Active AM is an iterative, structured approach to decision-making
that provides information that can lead to dynamic, state-
dependent decision recommendations, encouraging the incorpora-
tion of real-time outbreak information to resolve uncertainty in
system parameters where necessary (Probert et al., 2011;
Westgate et al., 2013; Williams et al., 2011; Allen et al., 2011). It
is well-established in ecological fields, such as conservation and
resource management (Holling et al., 1978; Hilborn et al., 1988;
Walters, 1986), and has recently gained attention in the literature
surrounding epidemiological interventions (Bradbury et al., 2017;
Shea et al., 2014; Li et al., 2017). However, widespread, interdisci-
plinary use has been hindered by a lack of consensus on the defini-
tion of AM and a lack of understanding as to how active AM differs
from current methods of management, such as ad hoc, trial-and-
error type approaches (Allen et al., 2011; Westgate et al., 2013;
Probert et al., 2011).
A major distinction between active AM and other approaches is
that it explicitly accounts for the effect that resolving uncertainty
will have on our ability to make optimal decisions. Under active
AM, we are able to observe that, with more information, the pre-
dicted efficacy of competing policies can change significantly and
a different policy may become optimal. There are therefore circum-
stances where it may be beneficial to choose an intervention policy
that allows for a rapid resolution of system uncertainty, as opposed
to a policy that may appear to provide better control under the cur-
rent level of information, but hinders the gathering of real-time
information.
In this work, we investigate how different methods of including
real-time information can affect policy selection during an epi-
demic and, in turn, how this affects our ability to satisfy the objec-
tives of management. We compare three approaches to managing a
theoretical epidemic: non-AM, passive AM and active AM. The epi-
demic is represented by a deterministic, non-spatial Susceptible-
Exposed-Infected-Recovered (SEIR) compartmental model, with
control limited to vaccination of the susceptible population at a
fixed daily vaccination rate, restricted by a finite vaccine pool.
There is no uncertainty regarding the spread of the disease in the
absence of control, however a single source of uncertainty is intro-
duced through an unknown vaccine efficacy, defined as the proba-
bility that an administered vaccine will result in immunity.
Information regarding the vaccine efficacy can be collected
throughout the outbreak by monitoring a proportion of adminis-
tered vaccines for success: a successful vaccination results in com-
plete, indefinite immunity that takes effect, and can be tested,
immediately. Conversely, we assume that unsuccessful vaccina-
tions result in no immunity.
The non-AM approach represents a static control policy, in
which real-time information is not used to improve control. Under
this approach, there is a single decision opportunity at the start of
the outbreak (day 0), for which we must decide whether to imple-
ment a vaccination campaign or not. Hence, this approach resultsin either a static vaccination campaign that is implemented imme-
diately and continued until the vaccine pool is depleted, or no vac-
cination throughout. This approach provides a baseline for the
performance of control, or no control. The passive and active AM
approaches allow for adaptation of control on a single, predeter-
mined day during the outbreak (t). For these approaches, there
are two decision opportunities: the initial decision on day 0 and
a final decision on day t. The initial decision is whether or not
to implement a vaccination campaign immediately and continue
it until at least day t. The final decision is whether or not to vac-
cinate from day t until the vaccine pool is depleted (i.e. continue
an ongoing campaign, stop an ongoing campaign, start a campaign
or continue with no campaign). On day 0, for the initial decision,
we have only the ‘prior information’ regarding vaccine efficacy.
On day t, the results of monitored vaccinations, if any vaccinations
have been administered, are used to provide updated information
regarding vaccine efficacy. Hence, an initial decision to vaccinate
allows for the resolution of uncertainty in vaccine efficacy, whilst
an initial decision not to vaccinate does not. Passive AM does not
incorporate the effect of reducing uncertainty in the vaccine effi-
cacy into the initial decision, hence, whilst this information might
be used for the final decision, we do not plan to use it. As such, pas-
sive AM represents a reactive approach to incorporating real-time
information. Active AM explicitly incorporates the resolution of
uncertainty when assessing the initial decision. Therefore, if choos-
ing to vaccinate, thereby allowing uncertainty in vaccine efficacy to
be reduced, leads to significantly improved future management,
active AM will incorporate this information and the results will
support a decision to vaccinate immediately.
For the basis of this analysis, we focus on two scenarios, con-
trasted primarily by different management objectives. Scenario
1: we allocate a ‘cost’ to the epidemic, defined by a linear combina-
tion of the number of infections, vaccines administered and a fixed
cost associated with implementing a vaccination campaign. The
objective of management is to minimise the expected value of this
cost. This scenario could be likened to a non-fatal, human disease
context, or livestock disease context, where the cost of implement-
ing a vaccination campaign must be weighed against the expected
benefits resulting from the campaign. In this scenario, we parame-
trise the epidemic model using flu-like transmission, incubation
and recovery rates, with a basic reproductive number (R0) of 1.6.
The relative weights of infections and vaccinations in the calcula-
tion of cost are fixed for the main result, however the effect these
have on the result is explored in detail in the subsequent sensitiv-
ity sections.
Scenario 2: the objective of management is to minimise the
expected duration of the outbreak, regardless of the number of
infections caused or vaccines used. This scenario could be likened
to a livestock disease context in which there are significant daily
costs to the economy caused by an ongoing outbreak, such as loss
of exports or tourism. In such a context, regaining a ‘disease-free’
status as quickly as possible may be the primary concern. In this
scenario we parametrise the epidemic model with Foot-and-
Mouth-like transmission, incubation and recovery rates, with an
R0 of 2. The control restrictions (daily vaccination rate, vaccine pool
and t) used in each scenario are summarised in Table A.2, along-
side other fixed parameters. For both scenarios, the effects of
changing the epidemiological parameters used and the restrictions
on control are explored in detail in the sensitivity sections. The
treatment of such parameters in a real-world scenario, which are
likely to be uncertain rather than fixed, is addressed in the
discussion.
For both scenarios, we initially assume a large amount of uncer-
tainty in the vaccine efficacy at the start of the outbreak, or equiv-
alently, a very low amount of prior information, defined by a Beta
distribution centred around 50% efficacy with a high variance
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more prior information to inform our decisions is also explored
in detail.
We investigate the performances of the three approaches for
the two specific scenarios, showing that the method of incorporat-
ing real-time information can have a significant effect. We also
show how their performance changes under different conditions,
varying the amount of prior and real-time information available
from the outbreak, restrictions on control and epidemiological
parameters. Our focus on how passive approaches can lead to dif-
ferent results affecting control recommendations compared to
active approaches, specifically in the context of infectious disease
epidemics, extends similar explorations in both the ecological
and epidemiological literature (Shea et al., 2014; Moore et al.,
2017). Overall, we see that even highly simplified systems can be
difficult to control in the presence of uncertainty and the method
of incorporating real-time information into management decisions
can have a significant effect on policy selection. We find that active
AM is best able to provide information to meet management objec-
tives, whilst also providing more usable information to decision-
makers with regards to the collection of real-time information
and the timing and delivery of control.2. Materials and methods
2.1. Adaptive management
We provide a brief overview of the AM framework, in the con-
text of epidemic interventions, in Fig. 1. See also Table A.1 in
Appendix A. Similar applications in the literature include (Shea
et al., 2014; Bradbury et al., 2017; Li et al., 2017). For a more
detailed review of the AM framework in general we refer the
reader to (Allen et al., 2011; Westgate et al., 2013; Holling et al.,
1978; Walters, 1986; Hilborn et al., 1988; Probert et al., 2011).2.2. System representation
We describe the spread of a directly transmitted disease
throughout a population via a non-spatial, homogeneously mixing,
deterministic SEIR (Susceptible, Exposed, Infected, Recovered/
Removed) model, with constant transmission rate (b), incubation
rate (r) and recovery/removal rate (c; this can include both recov-
ery and death from the disease). We ignore demography on the
assumption that the dynamics of the epidemic are significantly fas-
ter than the natural birth–death process of the population. The
transmission, incubation and recovery rates used in each scenario
are provided in Table A.2. For both scenarios, the initial population
is made up of 5000 susceptible and 1 infected individual. We
assume that the epidemic is not detected until the number of
infected individuals reaches 20. We denote t as the number of days
since the epidemic was detected, with t ¼ 0 representing the day of
detection and initial management decision.
Control is limited to vaccination of the susceptible population.
We assume that vaccinations are perfectly targeted towards sus-
ceptible individuals, excluding the exposed class from vaccination,
to help clarify the link between uncertainty in vaccine efficacy and
the predicted outcome of control. Vaccinations can occur at a con-
stant daily rate (mr; number of vaccinations per day), restricted by a
limit on the total number of vaccines available (mpool). The vaccine
is assumed to result in immediate and indefinite immunity, with
probability me. This probability, the ‘vaccine efficacy’, is unknown
and provides the only source of uncertainty in the system.
A detailed, mathematical representation of the model can be
found in Appendix A.2, along with a summary of parameters and
notation used (Table A.2).2.3. Objectives of management
The objective of management differs between the two scenar-
ios, however can be summarised in general terms by defining a
flexible cost function that incorporates multiple factors: the dura-
tion of the outbreak, the number of vaccines administered, a fixed
cost associated with implementing a vaccination campaign and the
number of infections caused by the epidemic. In both scenarios, the
objective of management is to optimise the expected outcome of
the outbreak, over the unknown vaccine efficacy. The cost function
and calculation of the expected outcome are detailed mathemati-
cally in Appendix A.3.2.4. Prior and real-time information
Prior and real-time information focuses on resolving the uncer-
tainty in the system introduced by an unknown vaccine efficacy
(me). We define this information in a quantitative manner using a
Beta distribution (see Appendix A.4 for details). This allows us to
define a mode of the distribution, representing an estimate of vac-
cine efficacy, and also a measure of how much weight we are giv-
ing to this estimate. In general, throughout we use a prior
distribution centred around 50% efficacy with a large variance, rep-
resenting a situation where we do not have a strong idea of what
the efficacy is, but are aware that it is less likely to be completely
effective (100% efficacy) or completely ineffective (0% efficacy).
Real-time information is collected throughout the outbreak by
monitoring a proportion (q) of administered vaccinations for suc-
cess. We assume that the success or failure of a vaccine can be
tested immediately after it is administered and this test will
always give the true result. Whilst this is an unrealistic assump-
tion, it allows us to clearly identify the relationship between mon-
itored vaccinations and the resolution of uncertainty in vaccine
efficacy. This real-time information is combined with the prior
information using a Bayesian approach, to give a posterior distribu-
tion around the vaccine efficacy, also defined by a Beta distribution.
A detailed mathematical description of this process is provided
in Appendix A.4.2.5. Decision making approaches
In this work, we compare three approaches to decision making
during the outbreak: non-AM, passive AM and active AM. These
approaches are contrasted by how they incorporate real-time out-
break information, in this case the results of monitored vaccina-
tions. Under any of the three approaches, at each decision point
we must choose to vaccinate until the next decision point or not.
If there are no future decision points, this equates to vaccinating
until the vaccine pool is depleted, or forgoing vaccination for the
remainder of the epidemic. We allow a maximum of two decision
points (one for the non-AM approach): an initial decision is made
when the outbreak is detected (t ¼ 0) and a final decision is made
on a predetermined day during the outbreak (t ¼ t).
Under the non-AM approach we allow only the initial decision.
Under the adaptive approaches, a proportion of the vaccines
administered between the initial and final decision points, if any,
are monitored for success and this information is used to inform
the final decision. The adaptive approaches differ in how they
make the initial decision. Passive AM ignores the effect that
updated vaccine efficacy information may have on future deci-
sions, hence assumes that future decisions will be made using only
our prior level of knowledge. However, active AM explicitly
accounts for real-time information regarding vaccine efficacy and
anticipates how different outcomes from monitored vaccinations
may change our decisions in the future. The method of decision
Fig. 1. Adaptive management procedure. Adaptive management (AM) addresses the difficulties of epidemic control through a structured, iterative framework. The set-up
phase (dark grey circles) provides a quantitative representation of management objectives, possible actions, planned monitoring and system behaviour, decided upon a priori
with input from stakeholders. In the learning and implementation phase, the set-up components are used to forecast the possible effects of control. This allows a dynamic
policy recommendation, outlining the actions that will best satisfy the management objectives whilst predicting the possible effect of updated outbreak information on the
efficacy of control. As the epidemic progresses, predictions from competing models of system behaviour are compared to incoming information, reducing uncertainty in the
effect of control. The recommendations are adapted as necessary and the process repeats. Figure adapted from (Allen et al., 2011).
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is formalised mathematically in Appendix A.5.3. Results and discussion
3.1. Scenario 1
In the first scenario, we test our ability to minimise the ‘cost’ of
a theoretical epidemic. Cost is defined as a linear combination of
the number of infections caused by the outbreak, number of vacci-
nes administered and a fixed cost associated with implementing a
vaccination campaign (if one is implemented). The weight of each
contributing factor is defined relative to that of a single infection,
hence x2 ¼ 1 (see Appendix A.3). For the majority of the analyses
undertaken under this scenario we set the relative costs of vaccina-
tion to 0.6 per vaccine (x3 ¼ 0:6) plus a fixed cost of 350
(x4 ¼ 350) and assume that the epidemiological parameters are
representative of a flu-like disease such that the transmission rate
b ¼ 0:23, the incubation rate r ¼ 0:5 and the removal/recovery
rate c ¼ 0:14, with R0 ¼ 1:6. Vaccination is limited to 100 individ-
uals per day, with a total pool of 2500 vaccines. These parameters
are summarised in Table A.2. Sensitivity to all these parameters is
explored in detail in later sections.
With a maximum of two decision points (t ¼ f0; tg), there are a
maximum of four possible campaigns that may be implemented bythe end of the outbreak (Fig. 2): 1) V0;tend , vaccination is imple-
mented immediately and continued until the vaccine pool is
depleted, 2) V0;t , vaccination is implemented immediately and
stopped on day t, 3) Vt ;tend , vaccination is delayed until day t
, then
performed until the vaccine pool is depleted, and 4) V0;0, no vacci-
nes are administered during the outbreak. Under active and pas-
sive AM, all four of these campaigns are taken into consideration,
whilst under the non-AM approach only campaigns (1) and (4)
are considered.
Under the non-AM approach to management, the initial deci-
sion to vaccinate or not cannot be adapted. Hence, an initial deci-
sion to vaccinate is equivalent to committing to a full vaccination
campaign (V0;tend ; Fig. 3 red line) and an initial decision not to vac-
cinate is equivalent to foregoing vaccination for the duration of the
outbreak (V0;0; Fig. 3 blue line). Thus, under this approach, the opti-
mal policy is to not vaccinate initially, and throughout, since it pro-
vides a lower expected cost over the prior distribution around
vaccine efficacy than a full campaign. There is no opportunity to
adapt this, hence we would forego vaccination for the duration of
the outbreak under this approach.
Under passive AM, we recognise that an initial decision to vac-
cinate or not can be adapted on day t. Passive AM plans for this
adaptation based on the prior information regarding vaccine effi-
cacy. Hence, an initial decision to vaccinate is assumed to lead to
a final decision to also vaccinate, since, over the prior distribution,
Fig. 2. Scenario 1: Predicted outbreak cost resulting from possible two-phase campaigns. For the passive and active AM methods, the two decision points (t ¼ f0; tg)
result in four possible two-phase campaigns that may be implemented by the end of the outbreak: 1) vaccination is started immediately and continued until the vaccine pool
is depleted, 2) vaccination is started immediately but stopped on day t , 3) vaccination is delayed until t , then continued until the vaccine pool is depleted, or 4) no
vaccination is employed during the outbreak. The non-AM approach has only one decision point (t ¼ 0), hence can only result in either campaign (1) or (4). Epidemiological
and vaccination parameters are set to those in Table A.2: Scenario 1. Expected cost is calculated over a Betað1:1;1:1Þ prior distribution around vaccine efficacy (see Appendix
A).
Fig. 3. Scenario 1: Predicted outbreak cost resulting from an initial decision to vaccinate or not. Predicted outbreak cost from implementing vaccination immediately
(red) or not (blue), as viewed under non-AM (A), passive AM (B) and active AM (C) methods. Dotted lines represent the expected cost, calculated over a Betað1:1;1:1Þ prior
distribution around vaccine efficacy (see Appendix A.4). Epidemiological and vaccination parameters are set to those in Table A.2: Scenario 1.
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cost than continuing it (Fig. 2). Thus, the expected cost of an initial
decision to vaccinate is equivalent to the expected cost of an
immediate, full campaign (V0;tend ) under passive AM (Fig. 3 red
line). Similarly, an initial decision not to vaccinate is assumed to
always result in no vaccination throughout the outbreak, since a
delayed, full campaign (Vt ;tend ) results in a higher expected cost
than no vaccination throughout (V0;0) over the prior distribution
(Fig. 2). Hence, under passive AM, the expected cost of an initial
decision not to vaccinate is equivalent to the expected cost of fore-
going vaccination completely (Fig. 3 blue line). Therefore, the opti-
mal policy for passive AM is an initial decision not to vaccinate,
since the expected cost of not vaccinating throughout is less than
the expected cost of an immediate, full campaign. Since we do
not have any vaccinations to monitor, no new information is avail-
able on day t and thus the final decision will also be to not
vaccinate.
Under active AM, we again recognise that an initial decision to
vaccinate or not can be adapted on day t, but also that this will
depend on the results of monitored vaccinations. Hence, an initialdecision to vaccinate is assumed to lead to continued vaccination if
the success rate from monitored vaccinations is sufficiently high
(larger than approximately 40%, based on the parameters we have
chosen), otherwise vaccination will be stopped on day t. Thus, the
expected cost of an initial decision to vaccinate is derived from a
combination of campaigns 1 and 2 (Fig. 3 red line): if the true vac-
cine efficacy is low, we are likely to get a low success rate from
monitored vaccinations and stop the campaign, whereas if true
efficacy is high the opposite will occur. Close to the value of vac-
cine efficacy where the cost of stopping and continuing the cam-
paign cross over (approximately 40%), there is still uncertainty
as to which choice is optimal even with the results from monitored
vaccinations, hence the expected cost is increased slightly by the
possibility of making the wrong decision. In contrast, an initial
decision not to vaccinate results in there being no vaccinations to
monitor. Hence, as under passive AM, the expected cost of such
an initial decision is equivalent to the expected cost of foregoing
vaccination for the entire outbreak (V0;0; Fig. 3 blue line). The opti-
mal policy for active AM is to vaccinate initially, since the benefit
from learning, and the ability to stop the campaign if vaccine effi-
6 B.D. Atkins et al. / Journal of Theoretical Biology 506 (2020) 110380cacy is proving to be low, outweighs the perceived benefit of not
vaccinating at all. In this scenario, if we were to implement this
policy, it would result in 35 monitored vaccinations by day t. If
at least 14 of these result in immunity, we would continue vaccina-
tion on day t, otherwise we would stop the campaign.
In summary, we observe that the three methods of incorporat-
ing the information frommonitored vaccinations result in different
management decisions. The optimal policy for both a non-AM and
passive AM approach is to forego vaccination for the entirety of the
outbreak, since, under the prior distribution, the expected benefit
of a full vaccination campaign is not sufficient to offset the cost
of the vaccines. However, under active AM, we recognise that an
ineffective campaign can be stopped on day t, saving the cost of
administering the remaining vaccines and thus lowering the over-
all expected cost of immediate vaccination. Hence, the optimal pol-
icy for active AM is to start vaccination immediately and continue
until the vaccine pool is depleted if monitored vaccinations are
successful (in this scenario, if at least 14 of the 35 monitored vac-
cinations are successful), otherwise cease vaccination on day t. In
this scenario, by incorporating the possible future results of mon-
itored vaccinations into our initial decision, following active AM
would reduce the expected cost of the outbreak by over 100 units
(approximately 3%) compared to following a passive or non-AM
approach. Hence, only active AM truly satisfies our management
objective of minimising expected outbreak cost.3.2. Scenario 2
In the second scenario we focus on our ability to minimise the
duration of a theoretical epidemic (x1 ¼ 1;x2 ¼ x3 ¼ x4 ¼ 0;
see Appendix A.3). Such an objective that may be suitable for some
livestock disease epidemics, for which eradicating the disease as
quickly as possible is the primary concern, in order to minimise
the impact on the economy through exports and tourism. We
parameterise the epidemiological model using FMD-like parame-
ters; transmission: b ¼ 0:2, incubation: r ¼ 0:2 and removal/re-
covery: c ¼ 0:1, with R0 ¼ 2. Vaccination is limited to 100
individuals per day, with a total pool of 4500 vaccines. These areFig. 4. Scenario 2: Predicted outbreak duration resulting from possible two-phas
(t ¼ f0; tg) result in four possible two-phase campaigns that may be implemented by th
vaccine pool is depleted, 2) vaccination is started immediately but stopped on day t , 3) v
no vaccination is employed during the outbreak. The non-AM approach has only o
Epidemiological and vaccination parameters are set to those in Table A.2: Scenario 2. Ex
efficacy (see Appendix A.4).summarised in Table A.2. Sensitivity to all these parameters is
explored in detail in later sections.
As in scenario 1, there are a maximum of four possible cam-
paigns that may be implemented by the end of the outbreak
(Fig. 4). Compared to scenario 1, the behaviour of the objective
over the range of vaccine efficacy in this scenario is less intuitive.
Here, if vaccine efficacy is low or too few vaccines are adminis-
tered, we may see an increase in outbreak duration compared to
taking no action. This occurs if the vaccination campaign is not suf-
ficient to reduce the effective R0 of the epidemic below 1 before it
is stopped, leading to a longer, albeit much smaller, outbreak.
Another consequence of this is that a delayed campaign (3:
Vt ;tend ) can be more effective at shortening duration than an imme-
diate campaign, since a delayed campaign allows the disease to
spread unhindered for 7 days before vaccination is implemented,
hence the outbreak burns through the population faster. In sce-
nario 1, when the number of infections was important not dura-
tion, a delayed campaign was never considered more effective
than an immediate one.
Under the non-AM approach, we only compare campaigns (1:
V0;tend ) and (4: V0;0): immediate, full vaccination or no vaccination
respectively. The expected duration over the prior distribution
around vaccine efficacy is lower for the former, hence the optimal
policy for this approach is to vaccinate immediately and continue
vaccination until the vaccine pool is depleted.
Under passive AM, an initial decision to vaccinate is assumed to
always result in continued vaccination after day t, since stopping
the campaign results in a higher expected duration over the prior
distribution (Fig. 4). Hence, the expected duration from an initial
decision to vaccinate is equivalent to the expected duration from
an immediate, full campaign (Fig. 5 red line). In contrast to sce-
nario 1, an initial decision not to vaccinate is assumed to result
in vaccination from day t, hence leading to a delayed campaign
(Vt ;tend ), since this provides a lower expected duration over the
prior distribution than not vaccinating throughout the outbreak
(Fig. 4). Thus, in making the initial decision under passive AM,
we compare the expected duration of an immediate, full campaign
and a delayed campaign. In this case, the latter provides the loweste campaigns. For the passive and active AM methods, the two decision points
e end of the outbreak: 1) vaccination is started immediately and continued until the
accination is delayed until t , then continued until the vaccine pool is depleted, or 4)
ne decision point (t ¼ 0), hence can only result in either campaign (1) or (4).
pected duration is calculated over a Betað1:1;1:1Þ prior distribution around vaccine
Fig. 5. Scenario 2: Predicted outbreak duration resulting from an initial decision to vaccinate or not. Predicted outbreak duration from implementing vaccination
immediately (red) or not (blue), as viewed under non-AM (A), passive AM (B) and active AM (C) methods. Dotted lines represent the expected duration, calculated over a
Betað1:1;1:1Þ prior distribution around vaccine efficacy (see Appendix A.4). Epidemiological and vaccination parameters are set to those in Table A.2: Scenario 2.
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icy for passive AM is to not vaccinate initially. Since our initial deci-
sion is not to vaccinate, no new information would be available on
day t, hence the final decision would be to vaccinate from this day
based on the prior distribution, leading to a delayed campaign.
Under active AM, we again recognise that an initial decision to
vaccinate can lead to a final decision to continue vaccination, lead-
ing to campaign 1: V0;tend , if the success rate of monitored vaccina-
tions is sufficiently high, or stop vaccination, leading to campaign
2: V0;t , if the success rate is low. In this case, at efficacies below
approximately 60%, it is more effective to stop vaccination on
day t than continue it. Formally, in this scenario, an initial decision
to vaccinate would lead to continued vaccination if there are at
least 21 successes from the 35 monitored vaccinations, as this
results in a posterior distribution around vaccine efficacy that
assigns a lower expected duration to continuing than stopping. If
there are less than 21 successful monitored vaccinations, we would
stop vaccination on day t. Hence, the expected cost of an initial
decision to vaccinate is a combination of campaigns (1) and (2)
(Fig. 5 red line). An initial decision not to vaccinate means there
are no monitored vaccinations to provide updated information
regarding the vaccine efficacy, hence, as under the passive AM
approach, the expected duration of such an initial decision is
equivalent to that of a delayed campaign (Fig. 5 blue line). For
active AM, the optimal policy is to vaccinate initially, since it pro-
vides a lower expected duration over the prior distribution, again
arising from the recognition that an ineffective campaign can be
stopped on day t, reducing the negative effects of such a
campaign.
Overall, as in scenario 1, we observe that the three methods of
incorporating the information from monitored vaccinations result
in different management decisions. Following a non-AM approach,
the optimal policy is to vaccinate immediately and continue this
until the vaccine pool is depleted. The optimal policy for passive
AM is to not vaccinate immediately, but start vaccination on day
t and continue until the vaccine pool is depleted. Finally, the opti-
mal policy for active AM is to start vaccination immediately and
continue until the vaccine pool is depleted if at least 21 of the 35
monitored vaccinations are successful, otherwise cease vaccination
on day t. By incorporating the possible future results of monitored
vaccinations into our initial decision, following an active AM
approach leads to an expected duration that is almost 30 days
shorter than if we followed a passive AM approach, a decrease of
approximately 12%. Again, active AM is therefore the only
approach that truly meets our objective to minimise the expected
outbreak duration.3.3. Prior information
Thus far, in both scenarios, we have assumed a very low level of
prior information regarding the efficacy of the vaccine, defined by a
Betað1:1;1:1Þ distribution (see Appendix A.4). If we increase the
amount of prior information available, in either scenario, it
becomes more likely that the approaches will make the same ini-
tial decision, since the information gained frommonitored vaccina-
tions has relatively less impact. Which choice is made, to vaccinate
initially or not, depends on the estimate of efficacy that is sug-
gested by the prior information (the mode of the distribution
x0
x0þy0) and the amount of information supporting this estimate
(x0 þ y0). In this section, we focus on the effect of changing the
prior information under scenario 2 (Figs. 6–9), however similar
conclusions can be drawn from scenario 1, for which the results
are provided in Appendix B (Figs. B.16, B.17, B.18).
Changing the prior distribution affects the expected duration of
all vaccination campaigns, except the ‘no vaccination’ campaign
(Fig. 6). This in turn affects the expected outcome of both an initial
decision to vaccinate and an initial decision to not vaccinate
(Fig. 7).
If the estimate of efficacy provided by the prior information
(columns in Figs. 6 and 7, x-axis in Fig. 8) is low, more weight is
given to the predicted duration at low efficacies, hence foregoing
vaccination entirely becomes the optimal campaign. If there is
enough information supporting this estimate, an initial decision
not to vaccinate is chosen by all approaches and, since there are
no vaccinations to monitor, the choice not to vaccinate will con-
tinue throughout the outbreak. The amount of information
required for this to occur depends on the approach used (Fig. 8).
Under passive AM, even with no prior information (a flat prior dis-
tribution over vaccine efficacy) we would choose not to vaccinate.
Under a non-AM approach, we require only a very small amount of
prior information suggesting efficacy is low to switch from vacci-
nating to not vaccinating. Finally, under active AM we require
slightly more information supporting a low estimate of efficacy
(x0 þ y0 > 2) to make the same switch, since it recognises the pos-
sibility that monitored vaccinations may reveal the vaccine efficacy
to be higher than estimated.
As the prior estimate of vaccine efficacy increases, more weight
is given to the predicted duration of the campaigns at higher effi-
cacies, hence both the immediate, full (1: V0;tend ) and delayed (3:
Vt ;tend ) campaigns become more effective under the prior distribu-
tion (Fig. 6). As a result, the expected duration from an initial deci-
sion not to vaccinate switches from being based on no vaccination
to delayed vaccination for both passive and active AM (Fig. 7).
Fig. 6. Example effect of prior information on the expected duration of the outbreak under each campaign. The expected duration of the outbreak under each campaign
is calculated over the prior distribution around vaccine efficacy, defined by a Betaðx0 þ 1; y0 þ 1Þ distribution (see Appendix A.4). We set x0 þ y0 ¼ 4 and vary the estimate of
vaccine efficacy (the mode of the distribution x0x0þy0) across columns. Row 1: visual representation of how the prior distribution changes with estimated efficacy. Row 2:
expected duration of the outbreak under each campaign for different estimates of vaccine efficacy. Epidemiological and vaccination parameters are set to those in Table A.2:
Scenario 2.
Fig. 7. Example effect of prior information on the expected duration of the outbreak given an initial decision to vaccinate or not. We set x0 þ y0 ¼ 4 and vary the
estimate of vaccine efficacy (the mode of the distribution x0x0þy0) across columns. Rows 1–3: predicted outbreak duration over vaccine efficacy, given an initial decision to
vaccinate (red) or not (blue), for different prior estimates of efficacy, as viewed under a non-AM, passive AM or active AM approach respectively. Bottom row: initial decision
made under each approach, for different prior estimates of efficacy: vaccinate (red) or don’t (blue). Epidemiological and vaccination parameters are set to those in Table A.2:
Scenario 2.
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shorter outbreak for very high vaccine efficacies (> 80%), com-
pared to a delayed campaign, under passive AM we require a sig-
nificant amount of prior information supporting an estimate this
high to change our initial decision (Fig. 8). Under active AM, how-
ever, at low efficacies the shorter predicted duration resulting from
vaccinating until day t and stopping if monitored vaccinations are
unsuccessful (campaign 2: V0;t ), compared to a delayed campaign
that must continue until all vaccines are used, allows the expected
duration of an initial decision to vaccinate remain lower than not
vaccinating. If vaccine efficacy is very high (> 80%) an immedi-
ate, full campaign is optimal, hence estimates in this range also
result in an initial decision to vaccinate. Only if there is strong prior
information supporting an estimate of efficacy between approxi-mately 55% and 75% will we opt not to vaccinate initially under
active AM, since between these values a delayed campaign is opti-
mal (Fig. 4).
The degree of agreement between passive and active AM
depends heavily on the prior estimate of efficacy and the strength
of information supporting this estimate (right-hand panel; Fig. 9).
For any estimate of efficacy, we require at least x0 þ y0 > 2 for the
approaches to agree. This equates to having the amount of infor-
mation that two monitored vaccinations would provide, prior to
the outbreak beginning. For some estimates, such as around 55%
and 80%, we require a very large amount of prior information
(x0 þ y0 > 20) for the approaches to agree, since, at these points,
the rank of the campaigns cross over causing uncertainty as to
which choice is truly optimal. This can result in significantly differ-
Fig. 8. Scenario 2: Initial decision made under each approach given different prior information. We define prior information using a Beta(x0 þ 1; y0 þ 1) distribution
(Appendix A.4) and vary the estimated efficacy (the mode of the distribution; x0x0þy0) and the amount of information supporting this estimate (x0 þ y0). Top row: difference in
expected duration between vaccinating initially or not, as viewed under each approach. Bottom row: initial decision made under each approach: vaccinate (red) or not (blue).
Epidemiological and vaccination parameters are set to those in Table A.2: Scenario 2.
Fig. 9. Scenario 2: Comparison of initial decision made between active and passive AM given different prior information. We define prior information using a Beta
(x0 þ 1; y0 þ 1) distribution (Appendix A.4) and vary the estimated efficacy (the mode of the distribution; x0x0þy0) and the amount of information supporting this estimate
(x0 þ y0). Left panel: difference in expected duration under active AM compared to passive AM. Right panel: agreement in initial decision between passive AM and active AM.
Epidemiological and vaccination parameters are set to those in Table A.2: Scenario 2.
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estimates around 55% where there is still a relatively high possibil-
ity that efficacy is low enough to extend the outbreak duration
(left-hand panel; Fig. 9). However, for estimates around 80%, whilst
the approaches may differ in initial decision, the expected dura-
tions under both are similar, since if vaccine efficacy is high there
is only a small difference implementing an immediate, full cam-
paign (1: V0;tend ) under active AM and a delayed campaign (3:
Vt ;tend ) under passive AM. Hence, a different initial decision does
not necessarily lead to a significantly different outcome in terms
of the management objective.
Finally, we note that our definition of prior information and
requirement that x0; y0 P 0, allows for at most one mode (or none,
in the case of a uniform prior). This excludes distributions with two
modes, at 0 and 1, that would result if we allowed 1 6 x0; y0 6 0.
Whilst a polarised belief around vaccine efficacy would be uncom-
mon, it could easily be incorporated into this framework. In this
scenario, where me ¼ 0 results in the outcome of all campaigns con-
verging, the mode at me ¼ 1 would dominate and immediate, full
vaccination would be the obvious choice under all managementapproaches. In scenario 1 (Figs. B.16,B.17,B.18), the campaigns
diverge at both extreme values of vaccine efficacy, vary almost lin-
early between and switch rank at close to 50% efficacy. Hence, our
decisions would be very similar to those we obtain under a uni-
modal distribution, following whichever mode carries the most
weight.
Overall, we find that as long as there is still significant uncer-
tainty as to which choice of initial action is best, even with prior
information, active AM will result in a lower expected cost than
passive AM and is hence the only approach that truly minimises
the expected duration of the outbreak given the information and
resources available.
3.4. Monitoring
For active AM, the initial control decision depends on the num-
ber of vaccinations that are monitored for success. This occurs
through the expected outcome given an initial decision to vacci-
nate (E½Cðaiv Þ; Eq. A.16, Appendix A.5), which will depend on
how the outcomes of monitored vaccinations affect the posterior
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an initial decision not to vaccinate does not depend on the num-
ber of monitored vaccinations since it does not allow monitor-
ing). We explain in detail this effect for scenario 2 (Fig. 10);
however analogous statements can easily be made for scenario
1 (Fig. B.19).
First, if no monitoring is planned, active AM views an initial
decision to vaccinate in the same way as passive AM, hence
assumes that the campaign will always be continued until all
vaccines are used since this produces a lower expected duration
than stopping the campaign on day t over the prior distribution
around vaccine efficacy. Thus, the expected duration from an
initial decision to vaccinate converges to that of an immediate,
full campaign at low monitoring proportions (top-left;
Fig. 10). In this case, we would make an initial decision not to
vaccinate, with the intention of vaccinating from day t instead,
as under passive AM.
As the amount of monitoring increases, the expected duration
from an initial decision to vaccinate diverges from that of an
immediate, full campaign, becoming a weighted combination of
both an immediate, full campaign (V0;tend ) and a campaign that is
stopped on day t (V0;t ; Fig. 10). This is the result of having mon-
itored vaccinations to inform the final decision: if successes are
low, stop the campaign, otherwise continue it. If we have only
one monitored trial, we require it to be successful to continue
the campaign. Even at low values of vaccine efficacy, there is still
a chance that the monitored vaccination will be successful, hence
the campaign may be continued when it should not be. The oppo-
site is true at high values of efficacy. As a result, the predicted dura-
tion does not coincide exactly to either of the two campaigns that
we can choose from, but rather a weighted average of the two.
With two monitored vaccinations, we require only one of the
two to be successful to continue the campaign. As the number of
monitored vaccinations continues to increase, the required num-
ber of successes approaches 60% of the total, as this is the value
of efficacy at which continuing the campaign becomes more effec-
tive than stopping it.
With more trials, the probability of making an incorrect final
decision decreases. That is, there is less chance of achieving higherFig. 10. Scenario 2: effect of monitoring proportion on the predicted outbreak durat
vaccine efficacy, given an initial decision to vaccinate (red) or not (blue), for different mon
brackets beside the proportion. The required number of successful vaccinations from th
lower left corner of each panel. The far right panel assumes perfect information is obtain
the final decision. Epidemiological and vaccination parameters are set to those in Tablethan 60% successes if the true vaccine efficacy is actually below
this, and vice versa. As a result, the predicted duration from initial
decision to vaccinate more closely approximates a stopped cam-
paign (V0;t ) at low efficacies and a full campaign (V0;tend ) at high
efficacies. Only at efficacy values close to 60% do we still see a sig-
nificant divergence from both. If we were to assume that monitor-
ing provided perfect information, as is the case when using metrics
such as the Expected Value of Perfect Information (EVPI) (Shea
et al., 2014; Bradbury et al., 2017), we assume that we always
make the correct final decision. This is equivalent to the posterior
distribution of vaccine efficacy being a single point at the true
value and results in a predicted duration from an initial decision
to vaccinate coinciding exactly with either the immediate, full
campaign or stopped campaign, with no divergence even when
close to the true efficacy (bottom-right; Fig. 10).
Overall, the effect of having more monitoring information
reduces the probability of making an incorrect final decision. For
both scenarios, this will lower the expected cost or duration from
an initial decision to vaccinate towards that provided by perfect
information (Fig. 11). We require only one monitored vaccination
to make learning about vaccine efficacy worthwhile, allowing an
initial decision to vaccinate to become the optimal decision. We
also see that, whilst we can always allocate more resources to
monitoring to lower the expected outcome towards that provided
by perfect information, the effect of doing so decreases and
becomes negligible after approximately 70 monitored vaccinations
(q ¼ 10%). If we were to assign a cost to monitoring itself, there
would be a point at which adding more monitoring would cost
more than it was worth, leading to a single minima which active
AM can be used to find (right-hand column; Fig. 11). For scenario
1, a cost per monitored vaccination equivalent to 25% of the cost
of an infection results in an optimal monitoring proportion of 5%.
Similarly, for scenario 2, a cost per monitored vaccination equiva-
lent to 10% of the daily cost of the outbreak results in an optimal
monitoring proportion of 5%. As the cost of monitoring increases,
the optimal monitoring proportion will clearly fall and the best
attainable outcome (expected cost or duration) will rise
(Fig. B.20). If the monitoring cost is high enough, an initial decision
to vaccinate may longer be optimal.ion given an initial decision to vaccinate or not. Predicted outbreak duration over
itoring proportions (q; Table A.2). The number of monitored vaccinations is given in
e total number monitored in order to make a decision to vaccinate is shown in the
ed after day t , that is, we will know the true vaccine efficacy exactly when making
A.2: Scenario 2.
Fig. 11. Effect of monitoring proportion on the expected cost/duration given an initial decision to vaccinate or not. Top row: expected cost (scenario 1) given an initial
decision to vaccinate (red) or not (blue) for a range of monitoring proportions, with and without a cost associated with monitoring (right and left panel respectively). ‘25% of
infection cost’ refers to the cost assigned to monitoring a single vaccination, relative to the cost of a single infection. Bottom row: same as top row for scenario 2. The dotted
red line represents the expected cost/duration given an initial decision to vaccinate, assuming monitored vaccinations provide perfect information after day t .
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The vaccination campaigns are defined by a fixed daily vaccina-
tion rate (mr), finite vaccine pool (mpool) and a single day on which
real-time information can be used to adapt control (t). In both sce-
narios, these conditions have so far been fixed (Table A.2); however
they have a significant effect on the decisions made by our
approaches, causing the outcomes to be trivial in some cases and
complex in others (Fig. 12).Fig. 12. Sensitivity of results to restrictions on control. Varying the vaccine pool (mpool)
change in expected cost/duration given both the campaigns (row 1) and initial decision un
each approach for different values of these parameters. Results for scenario 1 are displaye
all others constant at the values provided in Table A.2. Vertical dotted lines identify the
passive and active AM agree in their initial decisions are shaded grey.First, we vary the vaccine pool and keep the other two control
restrictions constant (1st and 4th columns; Fig. 12). In both scenar-
ios, if the vaccine pool is too small, we will choose to forego vacci-
nation for the entirety of the outbreak. In scenario 1, this is due to
the cost of implementing the vaccination campaign outweighing
the number of infections avoided, and in scenario 2, because
administering such a small number of vaccines is likely to increase
the duration of the outbreak even with a highly effective vaccine
(Fig. B.21). In scenario 1, we see that a very large vaccine pool, daily vaccination rate (mr) and length of the monitoring period (t), we display the
der each approach (row 2). The bottom row displays the initial decision made under
d on the left and scenario 2 on the right. Parameters a varied one at a time, keeping
default parameter values used throughout. Areas of the parameter space for which
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ative effect of each vaccine, in terms of the reduction in the number
of infections each causes, is diminished so much that the campaign
is no longer cost effective (Fig. B.21). However, if the vaccine pool is
neither too small nor too large to make the initial decision obvious,
our approaches will lead to different decisions. Furthermore, we
note that, if we were not to fix the vaccine pool, but rather try to
optimise its size, only active AM could be relied on to do so. This
is clear in the case of scenario 1: active AM can clearly identify that
a vaccine pool size of 2500 leads to the lowest expected cost from
the outbreak, since it minimises the expected cost of an initial deci-
sion to vaccinate (1st column; Fig. 12). However, both passive and
non-AM would suggest that 2000 vaccines is the optimal pool size,
if they were to vaccinate, since they are biased by the high cost of
an ineffective campaign, which is avoided under active AM since
we recognise that an ineffective campaign can be stopped before
the vaccine pool is depleted.13.
Next, we vary the daily vaccination rate, keeping the vaccine
pool size and t constant (2nd and 5th columns; Fig. 12). For both
scenarios, a high daily rate highlights no vaccination as the obvious
choice, although for slightly different reasons. In scenario 1, a high
daily rate improves the effectiveness of all vaccination campaigns,
however the benefit of being able to stop a campaign that is inef-
fective is removed, hence we can no longer exploit this through
active AM (Fig. B.22). In contrast, in scenario 2, a higher daily rate
worsens our campaigns, since the negative effects of vaccination
(increased duration at low vaccine efficacy) are exaggerated.
Alongside this, the benefit of stopping an ineffective campaign
under active AM is again reduced, hence the obvious decision
becomes to not vaccinate (Fig. B.22). However, if the daily vaccina-
tion rate is not too large (scenario 1: < 400, scenario 2: < 500), the
approaches will lead to different initial decisions. Again, we note
that if we wanted to optimise the daily rate rather than assume
it fixed, active AM is the only approach that can do so. This is high-
lighted in scenario 1: under active AM we identify a daily rate of
approximately 100 per day as the optimal (2nd column; Fig. 12),
allowing learning about vaccine efficacy without committing too
many vaccines early on. However, under a non-AM or passive
AM approach we would opt to vaccinate as quickly as possible.
Finally, we vary the day on which we use the results from mon-
itored vaccinations to adapt control (t), keeping the vaccine pool
size and daily rate constant (3rd and 6th columns; Fig. 12). For
both scenarios, if this day is too far in the future, an initial decision
not to vaccinate becomes the obvious optimal choice. For scenario
1, this will lead to a final decision also not to vaccinate, caused by
the fact that the benefit of stopping an ineffective campaign is
removed (as with a high daily vaccination rate), since most ofFig. 13. Scenario 1: initial decisions given different relative costs associated with v
associated with implementing a campaign (x4), relative to the cost per infection (x
vaccinating initially or not, as viewed under each approach (top row), and initial decision
passive AM and active AM. Black crosses represent the default values used in scenario 1the vaccine pool will have already been used. In scenario 2, the
benefit of stopping an ineffective campaign is also removed, but
the effectiveness of a delayed campaign is also increased due to a
longer delay (Fig. B.23). As a result, in this scenario high values
of t lead to the implementation of a delayed campaign under both
adaptive approaches, and an immediate, full campaign under a
non-AM approach. If we wished to optimise the length of this delay
in scenario 2, under a passive AM approach we would choose to
make the delay as long as possible, to optimise a delayed cam-
paign, whereas under active AM we could identify a better optimal
value for t of around 5 days (6th column; Fig. 12).
3.6. Management objective
It is clear from the contrast between scenarios 1 and 2 that the
management objective has a significant impact on the decisions
made under any of the three approaches. Furthermore, in scenario
1, the relative costs of infections compared to vaccinations will also
have such an influence. If the costs of vaccination (both per vaccine
costs,x3, and a fixed cost associated with implementing a vaccina-
tion campaign, x4; Appendix A.3) are sufficiently high, an initial
decision to vaccinate will not be deemed optimal under any
approach. Similarly, if these vaccination costs are sufficiently low,
vaccination becomes the obvious choice and we will choose to vac-
cinate under all approaches. However, there is a region in which
the choice is not so obvious, where the costs of vaccination may
be outweighed by the reduction in infections if the vaccine is effec-
tive, but may not if it is ineffective. It is in this region that the initial
decision differs between approaches: under active AM we choose
to vaccinate and thereby learn about the vaccine efficacy, allowing
greater reduction in infections if vaccine efficacy is high, but under
the non-AM or passive AM approaches we are unable to foresee the
greater worth of doing this and therefore choose not to vaccinate at
all.
3.7. Epidemiological parameters
The dynamics of the epidemic itself can also render the decision
making problem trivial or highly complex. For example, in scenario
1, if R0 is less than 1, the epidemic will die out very quickly by itself
and hence it is clearly not worth incurring the cost of implement-
ing a vaccination campaign, so under all approaches we would
choose not to vaccinate. However, if R0 > 1, we see that only under
active AM do we choose to vaccinate (Fig. B.24).
We see a similar, but more complex, relationship in scenario 2.
If R0 is very low (R0 < 1) or high (R0 > 8), the negative effects of
vaccination (increased duration at low vaccine efficacy) are dimin-accinations and infections. We vary the cost per vaccination (x3) and fixed cost
2 ¼ 1; see Appendix A.3). Left-hand panels: difference in expected cost between
made under each approach. Right-hand panel: agreement in initial decision between
(Table A.2).
Fig. 14. Scenario 2: Initial decisionmade under each approach, varying epidemiological parameters.We vary the epidemiological parameters describing transmission (b)
and recovery/removal (c). Top row: difference in expected duration between vaccinating initially or not, as viewed under each approach. Bottom row: initial decision made
under each approach: vaccinate (red) or not (blue). Black crosses represent the default values used in scenario 2 (Table A.2). Lines of constant R0 are identified with black lines.
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(Figs. 14 and 15). However, between these values, our decision
depends on the approach we take. This is most pronounced for
1 < R0 < 4, with slow recovery rates from infection (long infectious
periods). In such circumstances, under passive AM the apparent
benefit of a delayed vaccination campaign (under the prior distri-
bution) causes us to make an initial decision not to vaccinate, how-
ever this removes our ability to learn. The long infectious period
results in an exaggerated negative impact if vaccine efficacy is in
fact low. Under active AM however, we recognise this and make
an initial decision to vaccinate and learn about efficacy, allowing
us to avoid the significant negative impacts of an ineffective vac-
cine. For epidemics with higher transmission rates and shorter
infectious periods, the benefit of a delayed campaign may out-Fig. 15. Scenario 2: Comparison of initial decision made between active and passiv
parameters describing transmission (b) and recovery/removal (c). Left panel: differen
agreement in initial decision between passive AM and active AM. Black crosses represent
with black lines.weigh the benefit of learning and stopping an ineffective campaign
(Fig. B.25).
In reality we will often be dealing with epidemics with an R0 in
this range (1 < R0 < 4), for example Ebola, seasonal influenza, cho-
lera, plague, Zika, to name a few. Only rarely will a disease have an
R0 value significantly higher than this, such as measles, and if the
R0 is below 1 then it is unlikely to cause a significant outbreak
requiring complex control recommendations.4. Conclusion
In this paper we have developed a model to investigate the
effectiveness of adaptive management strategies to control out-e AM given different epidemiological parameters. We vary the epidemiological
ce in expected duration under active AM compared to passive AM. Right panel:
the default values used in scenario 2 (Table A.2). Lines of constant R0 are identified
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incorporating real-time information regarding the unknown effi-
cacy of a vaccine. Such approaches may be necessary in the context
of infectious disease outbreaks, in which resources are limited, so
must be used strategically, and the effectiveness of any vaccination
campaign at the start of an outbreak may be uncertain.
We have found that, not only the ability to adapt the control of
outbreaks in light of new information, but also the ability to fore-
see such adaptation, can have a significant effect on the recom-
mendations made and the outcome of the epidemic. Both passive
and active AM can improve on a non-AM approach by more appro-
priately timing the introduction of control or stopping an ineffec-
tive campaign when necessary. In a two-phase control set-up
such as this, should passive and active AM lead to the same initial
decision, both management strategies will result in the same out-
come. However, because of the way in which the approaches treat
an immediate campaign under uncertainty, they may lead to dif-
ferent initial decisions. In both scenarios we analysed, under active
AM, the ability to foresee the option of stopping an ineffective cam-
paign if monitored vaccinations are proving unsuccessful signifi-
cantly lowered the expected cost (or duration) that would result
from an initial decision to vaccinate, when compared with passive
AM. This led to an initial decision to vaccinate under active AM,
whilst under passive AM we would opt not to vaccinate from the
start of the outbreak, removing our ability to learn about vaccine
efficacy and ultimately increasing the expected cost (duration) of
the outbreak. Therefore, under active AM we are better able to
meet the objectives of management. This remained the case across
all sensitivity analyses, in which the use of active AM was always
at least as good, often better, for meeting management objectives
as using the other two approaches.
Although the main result in both scenarios could lead to con-
trasting recommendations when using passive versus active AM,
this is highly dependent on the parameters used. Under certain
conditions, the uncertainty around vaccine efficacy does not trans-
late into uncertainty regarding control preference. If taking no
action becomes the obvious choice, then all approaches could lead
to the same decision not to vaccinate. This is found to occur if the
vaccine pool is too small for a campaign to have a significantly pos-
itive effect, or similarly if the daily vaccination rate is too high,
monitoring period too long, or vaccines too expensive. Conversely,
immediate, full vaccination may also become the obvious choice if
the cost of vaccines is very low compared to the cost of an infection
(for scenario 1), or if the R0 of the outbreak is very low or high (for
scenario 2). It is plausible that, from a public relations point of
view, the cost of appearing not to be taking every possible action
to curb an outbreak would be considered high enough that not vac-
cinating initially would never be an option. However, this high-
lights another of the benefits of active AM: it provides a
complete, evidence based plan of action for all stages of the out-
break, providing a clear outline for control recommendations con-
ditional on different monitoring outcomes and the effect each will
have on our ability to satisfy management objectives. Access to this
information makes it easier to justify tough, and possibly unintu-
itive, decisions at early stages of the outbreak, if those decisions
are shown to significantly improve the outcome of control in the
future. Such scenarios are often not obvious from the outset, hence,
whilst an active AM approach may not result in a different recom-
mendation to less complex approaches, this cannot be known a pri-
ori. Therefore, active AM is useful even if just to confirm and
provide evidence supporting the obvious choice of action.
The prior information regarding vaccine efficacy also has a sig-
nificant effect on the recommendations resulting from each
approach, and the difference between the results. As the amount
of prior information increases, the relative importance of real-
time information is reduced, hence we expect the differencebetween the results from passive and active AM to be less. Intu-
itively, if prior information suggests efficacy is low, the approaches
are more likely to lead to not vaccinating, whereas if the estimate
of efficacy is high, the approaches are more likely to decisions to
vaccinate. However, if the prior information still leaves uncertainty
as to which campaign is optimal, due to a lack of information or the
estimate of efficacy being close to where campaigns switch rank,
we are likely to see a difference in results between the approaches.
Care should be taken when using prior information alongside
real-time information, since, if given too much weight (i.e. the vari-
ance of the prior distribution is too low), it can render the latter
redundant. If prior information has been taken from previous out-
breaks, it may be inaccurate and hence lead to suboptimal manage-
ment. For example, in scenario 2, if prior information suggests that
vaccine efficacy is between 60–80%, but it is actually significantly
lower, relying heavily on this information may lead to opting for
a delayed campaign under both active and passive AM, when not
vaccinating is truly optimal. This would cause a significant increase
in the duration of the outbreak. However, if we reduce the weight
we place on prior information, active AM can incorporate the pos-
sibility that the true efficacy may still be low and hence results
could suggest to vaccinate immediately, reduce uncertainty and
stop the campaign if vaccine efficacy is proving to be lower than
expected, thereby avoiding much of the negative impact of an inef-
fective campaign. .
Under active AM, it is also possible to provide more relevant
information to decision-makers regarding the amount of monitor-
ing required and the timing and delivery of the vaccines. If there is
a cost associated with monitoring, as we would expect in reality,
the use of active AM can help to identify the point at which mon-
itoring no longer provides enough information regarding vaccine
efficacy to offset the cost of that monitoring. This helps to avoid
wasting resources on monitoring that will not affect the control
recommendations, possibly allowing more resources to be allo-
cated to control itself. Similarly, under active AM we can optimise
the delivery of control through the vaccine pool size, daily vaccina-
tion rate and length of the monitoring period. This would not be
possible under the other approaches.
In this paper we have focused upon a relatively simple non-
spatial model, with non-specific parameters chosen to mirror com-
mon non-fatal, human and livestock diseases. We have addition-
ally only focused upon a single uncertainty upon vaccine efficacy
to highlight the interaction between control and learning and
demonstrate the utility of active AM. In reality, epidemics are
much more complex and there are likely to be multiple interacting
uncertainties. For novel outbreaks, we may be unaware of the
transmission characteristics in the early stages and therefore
would not be able to fix the disease parameters as we have in this
work. However, it may still be necessary to introduce a control pol-
icy rapidly despite the underlying uncertainty. In such circum-
stances, we are able to treat these parameters as we have
vaccine efficacy, defining a prior distribution, possibly using histor-
ical data, and using active AM to guide implementation of an opti-
mal multi-phase control policy that explicitly considers resolution
of uncertainty as data are accrued during an outbreak. We would
expect the potential of active AM to be even greater in such a sce-
nario, when uncertainty is more prominent and therefore the cor-
rect course of action based on prior information alone is less clear.
It is certainly true that following an active AM approach to man-
agement will never result in a worse outcome compared to follow-
ing a passive or non-AM approach. However, in order to implement
and benefit from such an approach in the real world, greater
emphasis must be placed on ensuring the components of the AM
framework are in place before making management decisions. That
is, policy makers must have a clear idea of the objectives they wish
to satisfy, the control options available and the data that is going to
B.D. Atkins et al. / Journal of Theoretical Biology 506 (2020) 110380 15be collected throughout the outbreak, before making an initial con-
trol decision. This information helps to avoid scenarios in which
initial control hinders the resolution of uncertainty and our ability
to make optimal control decisions in the future. Although, even if
all components are clearly and quantitatively defined, the compu-
tational complexity of performing active AM can be a barrier to its
implementation in real time, leading to the use of sub-optimal pas-
sive or non-AM approaches instead. Tackling this issue is a signif-
icant focus of current and future work, with possible solutions in
areas such as machine learning (Probert et al., 2019).
Whilst analyses of similar systems exist in the literature, for
example (Shea et al., 2014; Moore et al., 2017), this paper has
extended on such work in two main areas. First, we have applied
the adaptive management methodology specifically to an infec-
tious disease epidemiology context and explored in depth how
passive and active AMmethods can lead to contrasting recommen-
dations at the start of an outbreak. Also, we have not relied upon
metrics that assume the complete resolution of uncertainty, such
as EVPI, but rather defined a hypothetical, Bayesian method of
uncertainty resolution that allows time-dependent, partial resolu-
tion of the uncertainty in vaccine efficacy. The methodology we
have introduced in this paper allows for the investigation of rela-
tively unexplored areas in the epidemiological literature, for exam-
ple the balance of resources between uncertainty resolution and
control actions, an area that has received significant attention in
the conservation and resource management literature (Moore
et al., 2017; Probert et al., 2011; Bogich et al., 2008; Baxter and
Possingham, 2011; Grantham et al., 2009) but not for epidemiolog-
ical interventions. The methodology also allows us to clearly exam-
ine the effect that control actions can have on our ability to resolve
uncertainty. In the context we have used, the resolution of uncer-
tainty is directly linked to the control action available, as in similar
applications in the literature (Runge, 2013), since we are not able
to monitor vaccinations without administering them. However,
this also applies in contexts where there is not a clear, inherent link
between control and monitoring. For example, in the case of uncer-
tain epidemiological parameters, control actions may also indi-
rectly affect the gathering of information by hindering the
collection of accurate transmission and recovery information
through lower disease prevalence or premature removal. This
methodology can be used to exemplify how active AM is able to
identify and exploit such effects.
In future work we intend to apply this methodology to more
realistic, data driven systems in order to further exhibit the utility
of active AM as a tool to help inform policy during real-world out-
breaks. In this way, we will develop models that can assist in the
development of adaptive intervention policies for novel disease
outbreaks, thus helping to reduce the impact of such epidemics
in the future.CRediT authorship contribution statement
Benjamin D. Atkins: Conceptualization, Methodology, Formal
analysis, Investigation, Writing - original draft, Writing - review
& editing, Visualization. Chris P. Jewell: Conceptualization, Writ-
ing - review & editing, Supervision, Funding acquisition. Michael
C. Runge: Conceptualization, Writing - review & editing, Funding
acquisition. Matthew J. Ferrari: Conceptualization, Writing -
review & editing, Funding acquisition. Katriona Shea: Conceptual-
ization, Writing - review & editing, Funding acquisition. William J.
M. Probert: Conceptualization, Writing - review & editing, Funding
acquisition. Michael J. Tildesley: Conceptualization, Methodology,
Writing - original draft, Writing - review & editing, Supervision,
Funding acquisition.Acknowledgements
This work was supported by a grant from the Biotechnology and
Biological Sciences Research Council (BB/K010972/4; www.bbsrc.
ukri. org), and from the Ecology and Evolution of Infectious Disease
program of the National Science Foundation (www.nsf.gov) and the
National Institutes of Health (1 R01 GM105247-01; www. nih.gov).
MJT and CJ received funding by the Research and Policy for Infec-
tious Disease Dynamics (RAPIDD) program of the Science and Tech-
nology Directorate of the Department of Homeland Security. Open
access funding was provided by UK Research and Innovation.




The differential equations for the system are:
dSðtÞ
dt ¼ bSðtÞIðtÞ  me  mrðtÞ;
dEðtÞ
dt ¼ bSðtÞIðtÞ  rEðtÞ;
dIðtÞ
dt ¼ rEðtÞ  cIðtÞ;
dRðtÞ
dt ¼ cIðtÞ þ me  mrðtÞ;
ðA:1Þ
where mrðtÞ depends on the current vaccination campaign. We
denote the vaccination campaign Vt0 ;t1 , representing a campaign
that starts on day t0 and ends on day t1. If t0 6 t 6 t1, we say the
campaign is currently ongoing and:
mrðtÞ ¼
mr ; if SðtÞ P mr;




mrðsÞds; if mpool 
R t
t0








If t < t0 or t > t1, the campaign is not currently ongoing and
mrðtÞ ¼ 0. If no vaccination occurs throughout the epidemic, we
denote this by V0;0. Note that mrðtÞ may also depend on the vaccine
efficacy me, through the depletion of S; we emphasise this with the
notation mrðt; meÞ where necessary.
Finally, tend represents the day on which the outbreak ends and
hence the duration of the outbreak (relative to the time of detec-
tion). This also depends on the vaccination campaign chosen and
vaccine efficacy. Given the continuous nature of the differential
equations (Eq. A.1), we define this to be the point at which the
number of Exposed and Infectious individuals together falls below
1 (EðtÞ þ IðtÞ < 1).
A summary of parameters and notation used can be found in
Table A.2.
A.3. Management objective
The cost of the outbreak, with a given vaccination campaign
(Vt0 ;t1 ) and vaccine efficacy (me), is calculated using a weighted, linear
combination of the duration of the outbreak, the number of vaccines
administered, a fixed cost associated with implementing a vaccina-
tion campaign and the number of infections caused by the epidemic:










þx4 dV ; ðA:3Þ
Table A.1
Components of the AM framework.
Management objectives
In order to decide upon the ‘best’ control action in the event of an epidemic outbreak, it is necessary to state the objectives that we wish to satisfy. Examples include
minimising the duration of the epidemic, loss of life, the economic cost, or, more realistically, a combination of such factors. Policy makers, in cooperation with
stakeholders, must explicitly state these goals a priori, in a quantifiable manner (Probert et al., 2011).
Control options
A list of possible controls that can be implemented throughout the outbreak. These must also be decided upon by policy makers in cooperation with stakeholders. The
AM framework forecasts and evaluates the implementation of these controls in different combinations throughout the outbreak to provide a structured, iterative
control recommendation.
Models of system behaviour
To predict how the disease may spread and how control actions will interact with this spread, quantitative models of system behaviour must be developed. It is
essential that competing models capture the key uncertainties within the system, those that affect the recommended course of action (Shea et al., 2014; Li et al.,
2017), as well as represent what is known or agreed about the system as accurately as possible. These models are compared and evaluated for credibility during the
outbreak. This component of the framework encompasses an impressive body of literature from the epidemiological community.
Monitoring plan
As the epidemic proceeds, it is possible to gather information about its behaviour from epidemiologists in the field and local community groups, such as the number of
infections or deaths daily, as well as the effect of interventions, for example the efficacy of vaccines. This allows the evaluation of competing control strategies and
models of system behaviour as the outbreak proceeds and is essential for resolving system uncertainty and improving control (Probert et al., 2011; Probert et al.,
2018). It is necessary to decide on what information to collect before choosing a control action, as this may restrict the resources available and can affect the utility of
some actions.
Management optimisation
The management objectives, control actions, models of system behaviour and monitoring plan are used to predict, with a level of uncertainty, the effect of interventions
under the different models. How the predictions are used depends on the optimisation method (Probert et al., 2011), including passive, trial-and-error type
approaches or active approaches to management in which the resolution of uncertainty is built into the optimisation procedure.
Implementation and adaptation
The final stage of the AM process is to implement a control action, based on the steps outlined so far, monitor the outbreak and use real-time outbreak information to
adapt future management to better accommodate the specified objectives. This may involve reassessing the credibility of competing models, comparing their
predictions to what actually happened. Models that are deemed to be less credible are given a lower weight in the optimisation process than those models that are
more credible (Probert et al., 2011).
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The cost in scenario 1 is defined by using non-zero weights for
x2;x3 and x4 and setting x1 ¼ 0. For scenario 2, we let
x2 ¼ x3 ¼ x4 ¼ 0 and x1 ¼ 1. The weights, xi, can either be unit-
less, representing the relative importance of each, or take a unit
such as currency. For example, x1 may be the daily loss of income
to the economy from reduced tourism or exports during the epi-
demic, x2 the total cost of care of an infected human or loss of
profit from having livestock infected,x3 the average monetary cost
of transporting and administering each vaccine and x4 the cost of
developing a new vaccine and marketing the campaign. The default
weights used for the basis of each scenario are given in Table A.2.
The expected cost of the outbreak is calculated by integrating
over the probability distribution around vaccine efficacy (Eq.
A.5). This distribution, f ðmeÞ, is defined in section A.3.
E½CðVt0 ;t1 Þ ¼
Z 1
0
CðVt0 ;t1 ; meÞ  f ðmeÞdme: ðA:5Þ
We approximate the integral in Eq. A.5 by binning vaccine effi-
cacy into 1% intervals.
A.4. Prior and real-time information
We define the prior information regarding vaccine efficacy
using a Betaðx0 þ 1; y0 þ 1Þ distribution (x0; y0 P 0). Hence, the
probability density function is:
f ðme; x0; y0Þ ¼
Cðx0 þ y0 þ 2Þ
Cðx0 þ 1ÞCðy0 þ 1Þ
mx0e ð1 meÞy0 ; ðA:6Þ
where CðÞ is the Gamma function. The mode of the distribution,
x0
x0þy0, corresponds to the estimate of vaccine efficacy. The sum
x0 þ y0 relates to the amount of information that is supporting the
estimate. For example, if the prior information is from a historical
vaccine trial, x0 could be the number of successful vaccinationsand y0 the number of unsuccessful vaccinations from the trial. How-
ever, to allow non-integer values of x0 and y0 in our analysis, we
define the sum x0 þ y0 to be the relative strength of the prior infor-
mation compared to a single monitored vaccination (introduced
below). If there is no prior information (x0 ¼ y0 ¼ 0), the distribu-
tion is uniform between 0 and 1 and hence the mode is undefined.
For the majority of this analysis, except when explicitly investigat-
ing the effect of prior information on our management decisions, we
set x0 ¼ y0 ¼ 0:1 (Table A.2) when defining our prior distribution
around vaccine efficacy. This results in a distribution centred
around 50% efficacy with a large variance, representing a situation
where we do not have a strong idea of what the efficacy is, but
are aware that it is less likely to be completely effective (100% effi-
cacy) or completely ineffective (0% efficacy).
Real-time information is collected throughout the outbreak by
monitoring a proportion (q) of administered vaccinations for suc-
cess. We assume that the success or failure of a vaccine can be
tested immediately after it is administered and this test will
always give the true result. We denote Mt as the total number of
vaccinations monitored up to time t, with xt and yt the number
of successful and unsuccessful vaccinations respectively (hence
Mt ¼ xt þ yt). This real-time information is combined with the
prior information to give a posterior distribution around the vac-
cine efficacy, defined by a Betaðx0 þ xt þ 1; y0 þ yt þ 1Þ distribution
with probability density function:
f ðme; x0; y0; xt; ytÞ ¼
Cðx0 þ xt þ y0 þ yt þ 2Þ
Cðx0 þ xt þ 1ÞCðy0 þ yt þ 1Þ
mx0þxte ð1 meÞy0þyt :
ðA:7ÞA.5. Decision making approaches
We allow a maximum of two decision points (one for the non-
AM approach): an initial decision is made when the outbreak is
detected (t ¼ 0) and a final decision is made on a predetermined
day during the outbreak (t ¼ t). We denote the choice to vaccinate
Table A.2
Summary of parameters and notation used. Scenario specific values apply throughout unless otherwise stated in the sensitivity sections. Values left blank depend on the
vaccination campaign and are calculated as required during the optimisation process.
Notation Description Scenario 1 value Scenario 2 value
b Transmission rate of disease 0.23 0.2
r Incubation rate of disease 0.5 0.2
c Recovery/removal rate from disease 0.14 0.1
mr Daily vaccination rate (number of individuals) 100 100
me Vaccine efficacy ð0;100Þ% ð0;100Þ%
mpool Total number of vaccines available 2500 4500
t Day on which adaptive approaches can adapt control 7 7
tend Day on which outbreak ends (duration of the outbreak) – –
Vt0 ;t1 Denotes a vaccination campaign that starts on day t0 and ends on day t1. We require t0 6 t1 6 tend – –
CðVt0 ;t1 ; meÞ Cost of an outbreak (HðtÞ) with a given vaccination campaign (Vt0 ;t1 ) and vaccine efficacy. – –
x1 Weight assigned to the length of the outbreak (per day) in calculation of cost 0 1
x2 Weight assigned to each infection caused by the outbreak in calculation of cost 1 0
x3 Weight assigned to each vaccination administered in calculation of cost 0.6 0
x4 Weight associated with a fixed cost of implementing a vaccination campaign in calculation of cost 350 0
x0 Number of successful vaccinations that form prior information regarding vaccine efficacy 0.1 0.1
y0 Number of unsuccessful vaccinations that form prior information regarding vaccine efficacy 0.1 0.1
q Proportion of administered vaccines monitored for success 5% 5%
Mt Number of vaccines monitored for success until time t – –
xt Number of successful, monitored vaccinations up to time t – –
yt Number of unsuccessful, monitored vaccinations up to time t – –
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f to represent the initial and final decisions respectively.
A.5.1. Non-AM
Initial decision (t ¼ 0) Since this is the only decision point
under this approach, a choice to vaccinate now (aiv ) implies vacci-
nation until vaccine pool depletion and a choice not to vaccinate
now (ai0) implies forgoing vaccination until the epidemic is over.
We compare the two choices by the expected cost of the outbreak
resulting from each (Eqs. A.8 and A.9), choosing that which pro-
duces the lowest expected cost over the prior distribution around
vaccine efficacy (f ðme; x0; y0Þ).
E½CðaivÞ ¼ E½CðV0;tend Þ ¼
Z 1
0
CðV0;tend ; meÞ  f ðme; x0; y0Þdme; ðA:8Þ
E½Cðai0Þ ¼ E½CðV0;0Þ ¼
Z 1
0
CðV0;0; meÞ  f ðme; x0; y0Þdme: ðA:9ÞA.5.2. Passive AM
Initial decision (t ¼ 0) Since there is a single future decision
point at t ¼ t, a choice to vaccinate initially (t ¼ 0) implies vacci-
nation until at least t, followed by either vaccination (leading to
the campaign V0;tend ) or no vaccination (V0;t ). Note that we
assume the ratio between the number of vaccines available and
the daily vaccination rate is such that the vaccine pool will not
be depleted before day t. Similarly, a choice not to vaccinate ini-
tially can result in forgoing vaccination completely (V0;0) or a
delayed campaign starting on day t (Vt ;tend ). When calculating
the expected cost of each initial action (Eqs. A.10 and A.11), we
assume that future decisions will be made optimally, given the
information we have. Under passive AM, we do not plan for mon-
itoring, hence we do not incorporate the anticipation of future
monitored vaccinations into our initial decision. Instead, we
assume that future decisions will be made based on the current
level of information, in this case the prior information. Hence,
the expected cost of an initial action under passive AM is the
minimum of the expected cost of the two campaigns that can
result from it, calculated over the prior distribution around vac-




















Final decision (t ¼ t) If the initial decision was to vaccinate
(aiv ), we make a final decision based on both the prior information
and monitored vaccinations. Since there are no more future deci-
sion points, this is a simple expectation over two choices: continue
vaccination, leading to campaign V0;tend (E½Cðaiv ; afv Þ; Eq. A.12), or
stop vaccinating, leading to campaign V0;t (E½Cðaiv ; af0Þ; Eq. A.13).
We choose the option that produces the lowest expected cost over
the posterior distribution around vaccine efficacy
(f ðme; x0; y0; xt ; yt Þ).




CðV0;tend ; meÞ  f ðme; x0; y0; xt ; yt Þdme; ðA:12Þ




CðV0;t ; meÞ  f ðme; x0; y0; xt ; yt Þdme: ðA:13Þ
If the initial decision was to not vaccinate (ai0), no new informa-
tion has been gained for the final decision, hence we use only the
prior information to make our final decision. Again, this is a simple
expectation of two choices (E½Cðai0; afv Þ and E½Cðai0; af0Þ; Eqs. A.14
and A.15) and we choose the option that produces the lowest
expected cost over the prior distribution around vaccine efficacy
(f ðme; x0; y0Þ). Note that the comparison of these two options has
already been performed during the initial decision when calculat-
ing the expected cost of an initial decision to not vaccinate (Eq.
A.11) and the result remains unchanged.




CðVt ;tend ; meÞ  f ðme; x0; y0Þdme; ðA:14Þ
Fig. B.16. Example effect of prior information on the expected cost of the outbreak given an initial decision to vaccinate or not. We set x0 þ y0 ¼ 4 and vary the
estimate of vaccine efficacy (the mode of the distribution x0x0þy0) across columns. Rows 1–3: predicted outbreak cost over vaccine efficacy, given an initial decision to vaccinate
(red) or not (blue), for different prior estimates of efficacy, as viewed under a non-AM, passive AM or active AM approach respectively. Bottom row: initial decision made
under each approach, for different prior estimates of efficacy: vaccinate (red) or don’t (blue). Epidemiological and vaccination parameters are set to those in Table A.2:
Scenario 1.
Fig. B.17. Scenario 1: Initial decision made under each approach given different prior information. We define prior information using a Beta(x0 þ 1; y0 þ 1) distribution
and vary the estimated efficacy (the mode of the distribution; x0x0þy0) and the amount of information supporting this estimate (x0 þ y0). Top row: difference in expected cost
between vaccinating initially or not, as viewed under each approach. Bottom row: initial decision made under each approach: vaccinate (red) or not (blue). Epidemiological
and vaccination parameters are set to those in Table A.2: Scenario 1.
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Z 1
0
CðV0;0; meÞ  f ðme; x0; y0Þdme: ðA:15ÞA.5.3. Active AM
Initial decision (t ¼ 0) As under passive AM, a choice to vacci-
nate initially (from t ¼ 0) implies vaccination until at least t, fol-
lowed by either continued vaccination (V0;tend ) or no vaccination(V0;t ), and a choice not to vaccinate initially can result in forgoing
vaccination completely (V0;0) or a delayed campaign starting on
day t (Vt ;tend ). When calculating the expected cost of each initial
action (E½Cðaiv Þ and E½Cðai0Þ; Eqs. A.16 and A.11), we assume that
future decisions will be made optimally, given the information
we have. In contrast to passive AM, under active AM we explicitly
incorporate the anticipation of results of future monitored vaccina-
Fig. B.18. Scenario 1: Comparison of initial decision made between active and passive AM given different prior information. We define prior information using a Beta
(x0 þ 1; y0 þ 1) distribution and vary the estimated efficacy (the mode of the distribution; x0x0þy0) and the amount of information supporting this estimate (x0 þ y0). Left panel:
difference in expected cost under active AM compared to passive AM. Right panel: agreement in initial decision between passive AM and active AM. Epidemiological and
vaccination parameters are set to those in Table A.2: Scenario 1.
Fig. B.19. Scenario 1: effect of monitoring proportion on the predicted outbreak cost given an initial decision to vaccinate or not. Predicted outbreak cost over vaccine
efficacy, given an initial decision to vaccinate (red) or not (blue), for different monitoring proportions (q; Table A.2). The number of monitored vaccinations is given in
brackets beside the proportion. The required number of successful vaccinations from the total number monitored in order to make a decision to vaccinate is shown in the
lower left corner of each panel. The far right panel assumes perfect information is obtained after day t , that is, we will know the true vaccine efficacy exactly when making
the final decision. Epidemiological and vaccination parameters are set to those in Table A.2: Scenario 1.
Fig. B.20. Effect of cost associated with monitoring on the optimal monitoring proportion and optimal expected cost/duration given an initial decision to vaccinate.
Top row: optimal monitoring proportion given an initial decision to vaccinate for a range of monitoring costs, for scenario 1 (left) and scenario 2 (right). Bottom row: optimal
expected outcome (cost or duration) given an initial decision to vaccinate for a range of monitoring costs.
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Fig. B.21. Effect of vaccine pool size on campaign performance – Scenarios 1 and 2. All other parameters are fixed to the values given in Table A.2. Asterisks identify the
default value for the vaccine pool size used in each scenario.
Fig. B.22. Effect of the daily vaccine rate on campaign performance - Scenarios 1 and 2. All other parameters are fixed to the values given in Table A.2. Asterisks identify
the default value for the daily rate used in each scenario.
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sions will be made based on not only the prior information, but
also the results of monitored vaccinations. Since we do not know
what the results of monitored vaccinations will be, we take an
expectation over all possible results, weighted by the likelihood
of observing these results given the prior information we have.
For each set of results, we assume that the future decision is made
optimally based on the information those results provide. There-
fore, the expected cost of an initial action under active AM is the
weighted sum of the minimum expected cost of the two campaigns
that can result from it, calculated over the posterior distribution














0 CðV0;t1 ;meÞf ðme;x0;y0;xt ;yt Þdme
  
f xt ;Mt ;x0;y0ð Þ;
ðA:16Þ
where yt ¼ Mt  xt and f xt ;Mt ; x0; y0ð Þ is the probability density
function of a Beta-Binomial distribution with parameters Mt ; x0
and y0. Note that with Mt ¼ 0, this reduces to Eq. A.10, hence, in
the absence of any monitored vaccinations, passive and active AM
are identical.
Fig. B.23. Effect of the value of t on campaign performance – Scenarios 1 and 2. All other parameters are fixed to the values given in Table A.2. Asterisks identify the
default value for t used in each scenario.
Fig. B.24. Scenario 1: Initial decision made under each approach, varying epidemiological parameters. We vary the epidemiological parameters describing transmission
(b) and recovery/removal (c). Top row: difference in expected cost between vaccinating initially or not, as viewed under each approach. Bottom row: initial decision made
under each approach: vaccinate (red) or not (blue). Black crosses represent the default values used in scenario 1 (Table A.2). Lines of constant R0 are identified with black lines.
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been administered, the expected cost of not vaccinating initially
(E½Cðai0Þ) is equivalent under active AM as under passive AM (Eq.
A.11).
Final decision (t ¼ t) Since there are no future decision points,
and hence no more opportunities to gather information and adapt
control, the final decision under active AM follows the exact samemethodology as under passive AM (Eqs. (A.12)–(A.15)), conditional
on the initial decision made. Note that, under active AM, we have
already performed all the necessary calculations to make this deci-
sion. If the initial decision was to vaccinate, we will have moni-
tored Mt vaccinations by day t and observed a given number of
successes and failures, xt and yt , leading to a posterior distribu-
tion around vaccine efficacy. The expected costs of continuing or
Fig. B.25. Effect of epidemiological transmission and recovery rates on campaign performance - Scenario 2. All other parameters are fixed to the values given in
Table A.2. The asterisk identifies the default combination of transmission and recovery rates used in scenario 2.
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(E½CðV0;tend Þ and E½CðV0;t Þ respectively) have already been calcu-
lated and compared within the calculation of expected cost of an
initial decision to vaccinate (Eq. A.16). Thus, rather than recalculat-
ing these expected costs, we are able to make the final decision
immediately given the number of successful vaccinations on day
t. Under passive AM, this would not be possible.
If the initial decision was to not vaccinate, no new information
has been gained and hence, as under passive AM, the campaign
that produced the lowest expected cost in the calculation of
E½Cðai0; af0Þ (Eq. A.11) would be chosen, without need for recalcula-
tion and comparison of these expected costs.
Appendix B. Results supplement
Figs. B.16, B.17, B.18, B.19, B.20, B.21, B.22, B.23, B.24, B.25.
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